Synergistic Use of Geniposide and Ginsenoside Rg1 Balance Microglial TNF-<svg  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg"   style="vertical-align:-0.2724495pt" id="M1" height="8.33029pt" version="1.1" viewBox="-0.0657574 -8.05784 10.38 8.33029" width="10.38pt"><g transform="matrix(.017,0,0,-0.017,0,0)"><path id="g14-223" d="M573 112L539 141C516 111 501 95 490 95C475 95 470 115 440 250C469 288 542 386 573 443L563 457L486 442C469 406 445 356 423 326H421C397 426 351 457 290 457C155 457 22 316 22 159C22 50 73 -12 138 -12C187 -12 255 15 333 123H335C348 19 378 -12 419 -12C467 -12 522 21 573 112ZM325 190C292 130 239 81 206 81C181 81 160 111 160 187C160 269 201 402 250 402C293 402 319 292 325 190Z" /><glyph.data ascent="3452" descent="-2858" horiz-adv-x="595" vert-adv-y="595" /></g></svg> and TGF-<svg  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg"   style="vertical-align:-4.1996pt" id="M2" height="16.4258pt" version="1.1" viewBox="-0.0657574 -12.2262 10.6211 16.4258" width="10.6211pt"><g transform="matrix(.017,0,0,-0.017,0,0)"><path id="g14-224" d="M587 567C587 643 528 699 441 699C385 699 326 676 277 633C198 563 165 487 133 308L60 -96C42 -194 34 -209 22 -223L30 -242C65 -238 129 -229 158 -199C168 -189 178 -156 198 -44L263 362C293 552 319 645 391 645C430 645 463 612 463 536C463 497 448 450 411 422C398 412 367 406 342 403L309 332C384 318 450 280 450 188C450 107 424 51 331 51C296 51 260 64 231 78L218 49C221 22 256 -18 290 -18C329 -18 371 0 418 25C483 59 582 141 582 235C582 323 524 365 448 398C523 441 587 481 587 567Z" /><glyph.data ascent="3452" descent="-2858" horiz-adv-x="609" vert-adv-y="609" /></g></svg>1 following Oxygen-Glucose Deprivation<i  > In Vitro</i>: A Genome-Wide Survey

<div>The top 10 pathways activated in the geniposide-treated group (a), ginsenoside-Rg1-treated group (b), and combination-treated group (c).</div>

Evidence-Based Complementary and Alternative Medicine

fig5

Figure 5

Figure 5: Synergistic Use of Geniposide and Ginsenoside Rg1 Balance Microglial TNF-<svg  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg"   style="vertical-align:-0.2724495pt" id="M1" height="8.33029pt" version="1.1" viewBox="-0.0657574 -8.05784 10.38 8.33029" width="10.38pt"><g transform="matrix(.017,0,0,-0.017,0,0)"><path id="g14-223" d="M573 112L539 141C516 111 501 95 490 95C475 95 470 115 440 250C469 288 542 386 573 443L563 457L486 442C469 406 445 356 423 326H421C397 426 351 457 290 457C155 457 22 316 22 159C22 50 73 -12 138 -12C187 -12 255 15 333 123H335C348 19 378 -12 419 -12C467 -12 522 21 573 112ZM325 190C292 130 239 81 206 81C181 81 160 111 160 187C160 269 201 402 250 402C293 402 319 292 325 190Z" /><glyph.data ascent="3452" descent="-2858" horiz-adv-x="595" vert-adv-y="595" /></g></svg> and TGF-<svg  xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg"   style="vertical-align:-4.1996pt" id="M2" height="16.4258pt" version="1.1" viewBox="-0.0657574 -12.2262 10.6211 16.4258" width="10.6211pt"><g transform="matrix(.017,0,0,-0.017,0,0)"><path id="g14-224" d="M587 567C587 643 528 699 441 699C385 699 326 676 277 633C198 563 165 487 133 308L60 -96C42 -194 34 -209 22 -223L30 -242C65 -238 129 -229 158 -199C168 -189 178 -156 198 -44L263 362C293 552 319 645 391 645C430 645 463 612 463 536C463 497 448 450 411 422C398 412 367 406 342 403L309 332C384 318 450 280 450 188C450 107 424 51 331 51C296 51 260 64 231 78L218 49C221 22 256 -18 290 -18C329 -18 371 0 418 25C483 59 582 141 582 235C582 323 524 365 448 398C523 441 587 481 587 567Z" /><glyph.data ascent="3452" descent="-2858" horiz-adv-x="609" vert-adv-y="609" /></g></svg>1 following Oxygen-Glucose Deprivation<i  > In Vitro</i>: A Genome-Wide Survey 

Figure 5 | Synergistic Use of Geniposide and Ginsenoside Rg1 Balance Microglial TNF- and TGF-1 following Oxygen-Glucose Deprivation In Vitro: A Genome-Wide Survey 